Recent reports indicate that renal injury molecule-1 (KIM-1) and Beta-2 microglobulin (β2MG), both involved in the development of systemic autoimmunity, may play a significant role in managing SLE patients, who are at a higher risk of tissue damage in multiple organs. Here, B2M is linked to systemic lupus erythematosus.